PRISMA 2020 Checklist
Section JOURNAL
and Item “Efficacy and safety of Sipjeondaebo-tang for cancer-related fatigue: A systematic review and meta-analysis”
TITLE: Checklist item Location where item is reported
Topic Journal of Ethnopharmacology
# 337 (2025) 118900; SJR 2024 : 1.142 Q1 H-Index : 243
Received 29 May 2024; Received in revised form 3 September 2024; Accepted 3 October 2024; Available online 4 October 2024
TITLE
Title 1 Identify the report as a systematic review. Halaman 1
Judul sudah
menyebutkan bahwa ini
adalah systematic review
and meta-analysis
ABSTRACT
Abstract 2 See the PRISMA 2020 for Abstracts checklist. Halaman 1
Tersedia latar belakang,
tujuan, metode, hasil,
dan kesimpulan, namun
tidak eksplisit mengikuti
format PRISMA
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of existing knowledge. Halaman 1-2
Latar belakang CRF
(cancer-related fatigue)
dan potensi SDT
dijelaskan dengan
komprehensif
Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. Halaman 2
Tujuan jelas: menilai
efektivitas dan
keamanan SDT terhadap
CRF
PRISMA 2020 Checklist
Section and Item
Checklist item Location where item is reported
Topic #
METHODS
Eligibility criteria 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. Halaman 3
Kriteria inklusi-eksklusi
dijelaskan (RCT, pasien
kanker dengan CRF,
intervensi SDT)
Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to Halaman 3
sources identify studies. Specify the date when each source was last searched or consulted.
9 database besar
disebutkan, dengan
tanggal pencarian 30
Nov 2023
Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. Halaman 3
Dijelaskan secara umum,
dan disebutkan detailnya
ada di Appendix 1
Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many Halaman 3
reviewers screened each record and each report retrieved, whether they worked independently, and if applicable,
details of automation tools used in the process. Dua peneliti independen,
konflik diselesaikan
reviewer ketiga
Data collection 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report, Halaman 3-4
process whether they worked independently, any processes for obtaining or confirming data from study investigators, and if
applicable, details of automation tools used in the process. Dua peneliti melakukan
ekstraksi data; tabel
Excel digunakan
Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each Halaman 3
outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used
to decide which results to collect. Outcome utama: skor
CRF; sekunder: kualitas
PRISMA 2020 Checklist
Section and Item
Checklist item Location where item is reported
Topic #
hidup & efek samping
10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding Halaman 3-4
sources). Describe any assumptions made about any missing or unclear information.
Data pasien, jenis
kanker, protokol
pengobatan, dll. juga
dikumpulkan
Study risk of bias 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many Halaman 4-5
assessment reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools
used in the process. Menggunakan Cochrane
RoB v2, dijelaskan per
domain
Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation Halaman 4
of results.
Menggunakan SMD &
MD, 95% CI, dan I²
untuk heterogenitas
Synthesis 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study Halaman 4
methods intervention characteristics and comparing against the planned groups for each synthesis (item #5)).
Studi diklasifikasi
berdasarkan jenis
kanker dan pengobatan
13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing Halaman 4
summary statistics, or data conversions.
Disebutkan
menghubungi penulis
jika ada data yang hilang
13c Describe any methods used to tabulate or visually display results of individual studies and syntheses. Halaman 5-8
Hasil disajikan dalam
grafik, tabel, dan forest
PRISMA 2020 Checklist
Section and Item
Checklist item Location where item is reported
Topic #
plot
13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was Halaman 4
performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and
software package(s) used. Random/fixed effect
model, I² untuk
heterogenitas, RevMan
digunakan
13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, Halaman 5-6
meta-regression).
Subgroup analysis dan
sensitivity analysis
dijelaskan
13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. Halaman 6
Analisis sensitivitas
dilakukan, misalnya
mengeluarkan studi Lei
(2021)
Reporting bias 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). Halaman 4
assessment
Funnel plot dilakukan
bila >10 studi (kondisi
ini terpenuhi)
Certainty 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. Halaman 4
assessment
Menggunakan GRADE
untuk setiap outcome
(rendah – sedang)
RESULTS
Study selection 16a Describe the results of the search and selection process, from the number of records identified in the search to the Halaman 5
number of studies included in the review, ideally using a flow diagram.
PRISMA 2020 Checklist
Section JOURNAL
and Item “Efficacy and safety of Sipjeondaebo-tang for cancer-related fatigue: A systematic review and meta-analysis”
TITLE: Checklist item Location where item is reported
Topic Journal of Ethnopharmacology
# 337 (2025) 118900; SJR 2024 : 1.142 Q1 H-Index : 243
Received 29 May 2024; Received in revised form 3 September 2024; Accepted 3 October 2024; Available online 4 October 2024
Diagram PRISMA
tersedia (jumlah awal:
430; final: 11 studi)
16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were Halaman 5
excluded.
Disebutkan alasan
eksklusi pada naskah
Study 17 Cite each included study and present its characteristics. Halaman 6-9
characteristics
Semua studi dijabarkan
dalam Tabel 2 dan 3
Risk of bias in 18 Present assessments of risk of bias for each included study. Halaman 5
studies
Gambar 2 menampilkan
grafik penilaian risiko
bias
Results of 19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect Halamn 6-9
individual studies estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.
Tiap studi dijabarkan
dengan data per
outcome
Results of 20a For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. Halamn 5-6
syntheses
Ringkasan hasil dan bias
per studi ada
20b Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary Halamn 6-8
estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing
groups, describe the direction of the effect. Hasil meta disajikan
lengkap (SMD/MD, CI,
I²)
20c Present results of all investigations of possible causes of heterogeneity among study results. Halamn 6
PRISMA 2020 Checklist
Section JOURNAL
and Item “Efficacy and safety of Sipjeondaebo-tang for cancer-related fatigue: A systematic review and meta-analysis”
TITLE: Checklist item Location where item is reported
Topic Journal of Ethnopharmacology
# 337 (2025) 118900; SJR 2024 : 1.142 Q1 H-Index : 243
Received 29 May 2024; Received in revised form 3 September 2024; Accepted 3 October 2024; Available online 4 October 2024
Subgroup dan
sensitivitas dibahas
20d Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. Halamn 6
Analisis sensitivitas hasil
disajikan
Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. Halaman 4
Funnel plot dijelaskan
untuk menilai potensi
publication bias
Certainty of 22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. Halaman 4
evidence
Level evidence: “low”
hingga “moderate”
tergantung outcome
DISCUSSION
Discussion 23a Provide a general interpretation of the results in the context of other evidence. Halaman 9-10
SDT efektif menurunkan
CRF & meningkatkan
QoL
23b Discuss any limitations of the evidence included in the review. Halaman 10
Banyak studi kualitas
rendah, metode
bervariasi, dan
heterogenitas tinggi
23c Discuss any limitations of the review processes used. Halaman 10
Disebutkan keterbatasan
publikasi dan variasi alat
PRISMA 2020 Checklist
Section JOURNAL
and Item “Efficacy and safety of Sipjeondaebo-tang for cancer-related fatigue: A systematic review and meta-analysis”
TITLE: Checklist item Location where item is reported
Topic Journal of Ethnopharmacology
# 337 (2025) 118900; SJR 2024 : 1.142 Q1 H-Index : 243
Received 29 May 2024; Received in revised form 3 September 2024; Accepted 3 October 2024; Available online 4 October 2024
ukur
23d Discuss implications of the results for practice, policy, and future research. Halaman 10
SDT menjanjikan, tapi
dibutuhkan RCT lebih
besar dan lebih kuat
OTHER INFORMATION
Registration and 24a Provide registration information for the review, including register name and registration number, or state that the review Halaman 2
protocol was not registered.
Terdaftar di PROSPERO:
CRD42024537788
24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. Tidak disebutkan tautan
ke protokol
24c Describe and explain any amendments to information provided at registration or in the protocol. Tidak dijelaskan
perubahan dari protokol
(jika ada)
Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the Halaman 10
review.
Tidak disebutkan adanya
pendanaan luar
Competing 26 Declare any competing interests of review authors. Halaman 10
interests
Tidak ada konflik
kepentingan
Availability of 27 Report which of the following are publicly available and where they can be found: template data collection forms; data Tidak disebutkan
data, code and extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.
other materials
ketersediaan data atau
kode
From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:
10.1136/bmj.n71
